Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Genentech Catching Up In Melanoma With Cotellic Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Cotellic/Zelboraf combination, but the company already is testing the addition of a PD-L1 inhibitor.


Related Content

Melanoma Approvals Break New Ground In Immunotherapy
PD-1 Progress May Shorten The Life Of Other Drugs
Franchise Management Likely To Be Theme Of 2015 Oncology Approvals
The Next Wave For Melanoma


Related Companies